Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Science"
DOI: 10.1111/cas.16401
Abstract: Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1‐like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate… read more here.
Keywords: like cells; mediated adcc; th1 like; expanded cells ... See more keywords
Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006440
Abstract: Key Points • Treatment with IL-15 before alemtuzumab was safe and led to decreased number and proliferative activity of T-cell leukemic cells.• IL-15 was associated with increased activation and proliferation of patient-derived NK and CD8+… read more here.
Keywords: cell; mediated adcc; augments cell; interleukin augments ... See more keywords